Skeletal muscle metabolism and Critical Illness Myopathy (CIM) during early course of systemic inflammation

Conditions

Critical illness myopathy (CIM) Signs and Symptoms Critical Illness Myopathy (CIM)

Grunow JJ, Reiher K, Carbon NM, Engelhardt LJ, Mai K, Koch S, Schefold JC, Z'Graggen W, Schaller SJ, Fielitz J, Spranger J, Weber-Carstens S, Wollersheim T.

2022-08-034 citations

10.1186/s13054-022-04101-1

Impact of protocol‐based physiotherapy on insulin sensitivity and peripheral glucose metabolism in critically ill patients

Niklas M. Carbon, Lilian Jo Engelhardt, Tobias Wollersheim, Julius J. Grunow, Claudia Spies et al. (9 authors)

Journal of Cachexia Sarcopenia and Muscle2022-01-2412 citations

10.1002/jcsm.12920

The E3 ubiquitin ligase TRIM62 and inflammation-induced skeletal muscle atrophy.

Schmidt F, Kny M, Zhu X, Wollersheim T, Persicke K, Langhans C, Lodka D, Kleber C, Weber-Carstens S, Fielitz J.

2014-09-2932 citations

10.1186/s13054-014-0545-6

Inflammation-Induced Acute Phase Response in Skeletal Muscle and Critical Illness Myopathy

Claudia Langhans, Steffen Weber‐Carstens, Franziska Schmidt, Jida Hamati, Melanie Kny et al. (22 authors)

PLoS ONE2014-03-2096 citations

10.1371/journal.pone.0092048

Critical illness myopathy and GLUT4: significance of insulin and muscle contraction.

Weber-Carstens S, Schneider J, Wollersheim T, Assmann A, Bierbrauer J, Marg A, Al Hasani H, Chadt A, Wenzel K, Koch S, Fielitz J, Kleber C, Faust K, Mai K, Spies CD, Luft FC, Boschmann M, Spranger J, Spuler S.

2012-12-1380 citations

10.1164/rccm.201209-1649oc

Interventions

Current intervention as of 15/10/2021: The following will be carried out in the Phase 1 observational pilot study: 1. Severity of illness, organ failure:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Critically ill patients with the Sequential Organ Failure Assessment (SOFA) score greater than or equal to 8 on 3 of the 5 successive days within 7 days after admission to ICU.

Exclusion criteria

Exclusion criteria: 1. Patients under age of 18 2. Missing written informed consent from a legal proxy 3. Pretreatment in ICU >7 days

Design outcomes

Primary

Measure	Time frame
Primary outcome measures for both observational and interventional studies: Insulin sensitivity: 1. Studies of the insulin receptor pathways such as IRS, PI3K, AKT and Glut4 will be performed 2. Glucose uptake as well as Insulin-Receptor kinase and PI3Kinase-activities will be determined 3. Hyperinsulinemic-euglycemic clamp will be performed Histopathology on muscle biopsies: Type II myosin loss will be investigated	—

Measure

Time frame

Primary outcome measures for both observational and interventional studies: Insulin sensitivity: 1. Studies of the insulin receptor pathways such as IRS, PI3K, AKT and Glut4 will be performed 2. Glucose uptake as well as Insulin-Receptor kinase and PI3Kinase-activities will be determined 3. Hyperinsulinemic-euglycemic clamp will be performed Histopathology on muscle biopsies: Type II myosin loss will be investigated

—

Secondary

Measure	Time frame
Secondary outcome measure for both observational and interventional studies: Electrophysiology: Measurement of membrane excitability	—

Countries

Germany

Outcome results

None listed